Expression ofRFG/ELE1?/ARA70 in normal and malignant prostatic epithelial cell cultures and lines: Regulation by methylation and sex steroids

Stimulation of Prostate Cancer Cellular Proliferation and Invasion by the Androgen Receptor Co-Activator ARA70β

“…The positive signal was blocked by antigenic peptide, and preimmune serum showed no immunoreactivity above background. These data correlate well with previous reports demonstrating that whereas ARA70␣ expression is decreased, 8,21 total ARA70 (␣ and ␤) is increased in prostate cancer, 17 suggesting ARA70␤ expression is increased in cancer.…”

“…21 We have reported that ARA70␣ mRNA is decreased in prostate cancer specimens by in situ hybridization. 8 Consistent with low ARA70␣ expression in cancer, overexpression of ARA70␣ reduced LNCaP cell proliferation.…”

Stimulation of Prostate Cancer Cellular Proliferation and Invasion by the Androgen Receptor Co-Activator ARA70β

“…The positive signal was blocked by antigenic peptide, and preimmune serum showed no immunoreactivity above background. These data correlate well with previous reports demonstrating that whereas ARA70␣ expression is decreased, 8,21 total ARA70 (␣ and ␤) is increased in prostate cancer, 17 suggesting ARA70␤ expression is increased in cancer.…”

“…21 We have reported that ARA70␣ mRNA is decreased in prostate cancer specimens by in situ hybridization. 8 Consistent with low ARA70␣ expression in cancer, overexpression of ARA70␣ reduced LNCaP cell proliferation.…”

Investigation of the Relationship Between Prostate Cancer andMSMBandNCOA4Genetic Variants and Protein Expression

“…The majority of early NCOA4 expression studies observed a decrease in mRNA transcript levels in prostate cancer compared to benign tissue [Li et al., ; Mestayer et al., ; Tekur et al., ]; however, one study noted an increase in expression in tumor compared to benign tissue [Hu et al., ]. We found no difference in protein expression levels between normal and cancerous tissue: there was intense NCOA4 staining in both cell types.…”

A Novel Splice Variant of the Nuclear Coactivator p120 Functions Strongly for Androgen Receptor: Characteristic Expression in Prostate Disease

“…The best characterized coactivator, SRC-1, and its mRNA levels appeared to be expressed at an equivalent amount in normal and tumour tissues [15,32]. In addition, expressions of ARA160, ARA54 and TRAP220 were not changed in prostate cancers [26]; however, Tekur et al found reduced levels of ARA70 expression in prostate cancer cell lines (LNCap, TSUPr1, DU145, PC3) compared with levels in normal prostatic epithelial cells [33]. Moreover, ARA55 expression levels in recurrent prostate cancers were significantly lower than in untreated prostate cancers [34].…”

Stimulation of Prostate Cancer Cellular Proliferation and Invasion by the Androgen Receptor Co-Activator ARA70β

“…The positive signal was blocked by antigenic peptide, and preimmune serum showed no immunoreactivity above background. These data correlate well with previous reports demonstrating that whereas ARA70␣ expression is decreased, 8,21 total ARA70 (␣ and ␤) is increased in prostate cancer, 17 suggesting ARA70␤ expression is increased in cancer.…”

“…21 We have reported that ARA70␣ mRNA is decreased in prostate cancer specimens by in situ hybridization. 8 Consistent with low ARA70␣ expression in cancer, overexpression of ARA70␣ reduced LNCaP cell proliferation.…”

Investigation of the Relationship Between Prostate Cancer andMSMBandNCOA4Genetic Variants and Protein Expression

“…The majority of early NCOA4 expression studies observed a decrease in mRNA transcript levels in prostate cancer compared to benign tissue [Li et al., ; Mestayer et al., ; Tekur et al., ]; however, one study noted an increase in expression in tumor compared to benign tissue [Hu et al., ]. We found no difference in protein expression levels between normal and cancerous tissue: there was intense NCOA4 staining in both cell types.…”

A Novel Splice Variant of the Nuclear Coactivator p120 Functions Strongly for Androgen Receptor: Characteristic Expression in Prostate Disease

“…The best characterized coactivator, SRC-1, and its mRNA levels appeared to be expressed at an equivalent amount in normal and tumour tissues [15,32]. In addition, expressions of ARA160, ARA54 and TRAP220 were not changed in prostate cancers [26]; however, Tekur et al found reduced levels of ARA70 expression in prostate cancer cell lines (LNCap, TSUPr1, DU145, PC3) compared with levels in normal prostatic epithelial cells [33]. Moreover, ARA55 expression levels in recurrent prostate cancers were significantly lower than in untreated prostate cancers [34].…”

Stimulation of Prostate Cancer Cellular Proliferation and Invasion by the Androgen Receptor Co-Activator ARA70β

“…The positive signal was blocked by antigenic peptide, and preimmune serum showed no immunoreactivity above background. These data correlate well with previous reports demonstrating that whereas ARA70␣ expression is decreased, 8,21 total ARA70 (␣ and ␤) is increased in prostate cancer, 17 suggesting ARA70␤ expression is increased in cancer.…”

“…21 We have reported that ARA70␣ mRNA is decreased in prostate cancer specimens by in situ hybridization. 8 Consistent with low ARA70␣ expression in cancer, overexpression of ARA70␣ reduced LNCaP cell proliferation.…”

Investigation of the Relationship Between Prostate Cancer andMSMBandNCOA4Genetic Variants and Protein Expression

“…The majority of early NCOA4 expression studies observed a decrease in mRNA transcript levels in prostate cancer compared to benign tissue [Li et al., ; Mestayer et al., ; Tekur et al., ]; however, one study noted an increase in expression in tumor compared to benign tissue [Hu et al., ]. We found no difference in protein expression levels between normal and cancerous tissue: there was intense NCOA4 staining in both cell types.…”

A Novel Splice Variant of the Nuclear Coactivator p120 Functions Strongly for Androgen Receptor: Characteristic Expression in Prostate Disease

“…The best characterized coactivator, SRC-1, and its mRNA levels appeared to be expressed at an equivalent amount in normal and tumour tissues [15,32]. In addition, expressions of ARA160, ARA54 and TRAP220 were not changed in prostate cancers [26]; however, Tekur et al found reduced levels of ARA70 expression in prostate cancer cell lines (LNCap, TSUPr1, DU145, PC3) compared with levels in normal prostatic epithelial cells [33]. Moreover, ARA55 expression levels in recurrent prostate cancers were significantly lower than in untreated prostate cancers [34].…”